RxDoctor Payments Data

Justin Abraham

Neurology · Santa Barbara, CANPI 1225322522

Payments from drug & device makers

$75,807in general payments, 2019–2025

Across 937 payments — averaging $80.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$31K
  • AbbVie$16K
  • Biohaven Pharmaceutical Holding Company Ltd.$11K
  • UCB, Inc.$2K
  • Neurelis, Inc.$2K
  • SK Life Science, Inc.$1K
  • plus $12K from 54 others

What the payments were for

  • Speaking & faculty fees$50,71367%
  • Travel & lodging$2,9314%
  • Food & beverage$22,13529%
  • Education$290%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biohaven Pharmaceuticals, Inc.50$31,201
AbbVie(2 entities)175$16,380
Biohaven Pharmaceutical Holding Company Ltd.25$11,402
UCB, Inc.60$1,610
Neurelis, Inc.31$1,604
SK Life Science, Inc.34$1,453
Biogen46$878
Novartis54$868
AstraZeneca(2 entities)19$837
Jazz Pharmaceuticals Inc.18$640
Pfizer44$637
Amgen36$623
Lundbeck LLC28$596
Lilly USA, LLC30$508
Teva Pharmaceuticals USA, Inc.34$503
TG Therapeutics, Inc.9$494
Greenwich Biosciences, Inc.12$370
Amneal Pharmaceuticals LLC14$282
Eisai Inc.14$271
Sanofi13$267
Johnson & Johnson(2 entities)13$253
EMD Serono, Inc.10$227
Genentech USA, Inc.10$226
Tanabe Pharma America, Inc.10$200
Supernus Pharmaceuticals, Inc.11$197
Ceribell, Inc.3$180
Neuropace, Inc.2$168
Livanova USA, Inc.5$166
Argenx US, Inc.6$157
Neurocrine Biosciences, Inc.8$154
Otsuka America Pharmaceutical, Inc.3$150
Sunovion Pharmaceuticals Inc.7$145
Abbott1$132
Acadia Pharmaceuticals Inc9$129
Upsher-smith Laboratories LLC8$123
Sumitomo Pharma America, Inc.5$99
Inspire Medical Systems, Inc.4$98
Octapharma USA, Inc.4$89
Kedrion Biopharma, Inc.3$88
Takeda Pharmaceuticals U.S.A., Inc.4$87
Vanda Pharmaceuticals Inc.3$86
Acorda Therapeutics, Inc4$80
Scilex Pharmaceuticals Inc.4$79
Catalyst Pharmaceuticals, Inc.3$75
Merz Pharmaceuticals, LLC3$67
Adamas Pharmaceuticals, Inc.4$58
Saol Therapeutics Inc.2$58
Cala Health, Inc.2$56
Mallinckrodt Hospital Products Inc.2$52
Bristol Myers Squibb3$51
CSL Behring3$49
Boston Scientific2$49
Arbor Pharmaceuticals, Inc.4$49
Impel Pharmaceuticals Inc.2$48
Grifols USA, LLC2$45
Averitas Pharma Inc.2$44
Alnylam Pharmaceuticals Inc.2$42
Noctrix Health, Inc.1$38
MDD US Operations, LLC2$38
E.r. Squibb & Sons, L.L.C.2$35

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$75,807 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$188,194
Medicare patients
485
Services billed
10,123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole24$26,050
Nurtec OdtRimegepant Sulfate15$23,836
QuliptaAtogepant20$22,854
HorizantGabapentin Enacarbil12$19,686
UbrelvyUbrogepant15$17,580
Aimovig AutoinjectorErenumab-Aooe13$9,455
Lacosamide45$3,899
Levetiracetam81$3,219
Topiramate ErTopiramate12$2,718
Carbidopa-LevodopaCarbidopa/Levodopa102$2,715
Memantine Hcl113$2,701
Carbamazepine ErCarbamazepine13$2,317
Pregabalin58$1,648
Gabapentin105$1,447
Donepezil Hcl182$1,180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$16,380$40,43435 claims
Otsuka America Pharmaceutical, Inc.Rexulti$150$26,05024 claims
PfizerNurtec Odt$637$23,83615 claims
Arbor Pharmaceuticals, Inc.Horizant$49$19,68612 claims
Upsher-smith Laboratories LLCTopiramate$123$74316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,996 neurology providers in California.

Other neurology in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →